The purpose of this study is to find out the safest dose of these modified cells that can be given to patients and to see how well the treatment works. The study will look at how many patients experience serious side effects within 28 days after receiving the treatment, which will help determine the best dose to use in the next part of the study. The study will also measure how well the treatment works by checking if the cancer responds to the treatment and how long patients remain free from disease.

During the study, patients will first have their own immune cells collected. These cells will then be modified in a laboratory to target the cancer cells. Before receiving the modified cells back, patients may receive chemotherapy to prepare their body for the treatment. After the modified cells are given through an infusion into a vein, patients will be monitored closely for side effects and to see how well the treatment is working. The study will follow patients for up to 12 months to track their progress and see if the cancer comes back. This study is for children and young adults between 1 and 45 years of age who have tried other treatments that did not work or who cannot receive other standard treatments.

The purpose of this study is to evaluate how well these treatments work in patients whose lymphoma has returned or did not respond to initial treatment. The study is divided into different treatment groups, with some patients receiving new targeted therapies while others receive combinations of standard chemotherapy medications.

During the study, patients will receive their assigned treatment and have regular medical evaluations to check how well the treatment is working. The treatment period may last up to 24 months, depending on which medication group the patient is assigned to. Doctors will monitor patients’ response to treatment using imaging scans and other medical tests to assess if the cancer is responding to the therapy.

The purpose of the study is to find the best dose of Glofitamab when used alone and in combination with Obinutuzumab, and to understand how safe and effective these treatments are for patients with this type of lymphoma. Participants in the study will receive these medications through an infusion, which means the medicine is given directly into the bloodstream through a vein. The study will monitor how the body responds to the treatment, including any side effects and how well the cancer responds.

Throughout the study, doctors will carefully observe the participants to ensure their safety and to gather information on how the treatment affects the cancer. The study aims to provide valuable insights into the potential benefits and risks of using Glofitamab and Obinutuzumab for treating relapsed/refractory B-cell non-Hodgkin’s lymphoma, which could lead to new treatment options for patients in the future.

Participants in the study will receive Axicabtagene Ciloleucel through an intravenous infusion, which means the treatment is given directly into the bloodstream. Before receiving this treatment, patients may also receive other medications, such as Cyclophosphamide and Fludarabine, which are used to prepare the body for the cell therapy. These medications help to create a more favorable environment for the modified T cells to work effectively. The study will monitor patients over time to assess their response to the treatment, including whether the cancer shows signs of improvement or remission.

The purpose of this study is to evaluate the effectiveness of Axicabtagene Ciloleucel in treating patients with DLBCL who have relapsed after their initial therapy. The trial will track various outcomes, such as the overall response rate, which measures how many patients experience a reduction in cancer symptoms, and the duration of response, which looks at how long the treatment remains effective. Additionally, the study will observe any side effects or adverse events that may occur during and after the treatment. The trial is expected to continue until 2031, providing valuable insights into the potential benefits and risks of this innovative therapy for DLBCL patients.

The purpose of the study is to determine how safe MB-CART2019.1 is and how well it works in treating these cancers. The study will also use other medications, including fludarabine, cyclophosphamide, and tocilizumab, which are given to help prepare the body for the cell therapy or to manage side effects. Participants will receive these treatments through an intravenous infusion, which means the medicine is given directly into a vein.

During the study, participants will receive the treatment and be monitored closely to see how their cancer responds and to check for any side effects. The study will take place over several months, with regular check-ups to assess the effectiveness of the treatment and the health of the participants. The goal is to find out if this new approach can provide a better outcome for children and adolescents with these challenging types of cancer.

Participants in the study will receive either the new treatment or the standard treatment. The new treatment, MB-CART2019.1, is given as an infusion, which means it is administered directly into the bloodstream through a vein. The standard treatment, R-GemOx, also involves infusions of the three medications. The study will monitor participants over a period to see how well the treatments work and to check for any side effects.

The study aims to find out if MB-CART2019.1 is more effective than the standard treatment in helping patients with R-R DLBCL who are not eligible for high-dose chemotherapy and stem cell transplantation. Participants will be closely monitored by healthcare professionals throughout the study to ensure their safety and to gather information on the effectiveness of the treatments.

Participants in the study will receive Mosunetuzumab either as a solution for injection under the skin or as a solution for infusion into a vein. The study will also explore how the body processes the medication, which is known as pharmacokinetics. Some participants will receive a combination of Mosunetuzumab and Atezolizumab, which is also given as a solution for infusion. The study will monitor the participants over time to assess how well the treatment works and to identify any side effects or adverse reactions.

The trial aims to determine the best dose and schedule for using Mosunetuzumab alone or with Atezolizumab. It will also compare the effectiveness of the treatment when given by different methods, such as injection versus infusion. The study is expected to continue until November 2025, and it will provide valuable information on the potential benefits and risks of these treatments for patients with Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia.

The purpose of the study is to evaluate the effectiveness of MB-CART2019.1 in treating DLBCL. Participants will first receive a preparatory treatment to reduce the number of existing immune cells, known as a conditioning lymphodepletion regimen, before receiving the MB-CART2019.1 infusion. The study will monitor the participants’ response to the treatment over time, assessing how well the cancer responds and any changes in the participants’ health. Some participants may receive a placebo as part of the study to compare the effects of the treatment.

Throughout the study, participants will undergo regular health assessments, including imaging tests like MRI to track the progress of the treatment. The study aims to determine the overall response rate, which includes both partial and complete responses to the treatment. Additionally, the study will evaluate the duration of the response, progression-free survival, and overall survival, as well as monitor any side effects or adverse events that may occur. The study is expected to continue until 2027, with recruitment starting in 2024.

The purpose of this study is to evaluate the long-term safety of these therapies. Patients who have received these treatments will be monitored over time to check for any late-onset side effects or serious health events. This includes looking for any new or returning cancers, serious infections, or other significant health issues. The study will also track the presence of certain cells in the blood, such as B and T lymphocytes, and other health indicators like height and weight in children. The presence of any remaining modified cells from the therapy will also be checked.

Participants in this study will have regular follow-up visits where their health will be assessed. This includes checking for any signs of the cancer returning or progressing and monitoring overall survival rates. The study aims to ensure that the treatments are safe in the long term and to gather important information that can help improve future therapies. The study is expected to continue until the end of 2040, providing valuable insights into the long-term effects of these innovative treatments.

The study will be conducted in different parts. Initially, the safety and tolerability of MEN1703 alone and in combination with Glofitamab will be assessed. This means researchers will monitor how well patients tolerate the medications and any side effects that may occur. Following this, the study will focus on the ability of these treatments to fight the lymphoma, which is a type of cancer that affects the lymphatic system, a part of the body’s immune system. The study will involve regular monitoring and assessments to track the progress and response of the cancer to the treatments.

Participants in the study will receive either the combination of MEN1703 and Glofitamab or MEN1703 alone. Some participants may also receive a placebo, which is a substance with no active medication, to help compare the effects of the treatments. The study aims to provide valuable information on the potential benefits and risks of these treatments for patients with this challenging form of lymphoma. The trial is expected to continue until the end of 2026, with recruitment starting in late 2024.